IRulya Therapeutics Inc. (IRLA) Stock Forecast
IRLA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.56 / 5 from 9 analysts
- Price target
- $75.00 average of analyst targets
- Upside to target
- +134.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.83
- 52-week range
- $16.00 – $880.00
IRLA analyst ratings
9 analystsNumber of analysts at each rating.
IRLA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IRLA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.20 | −$1.40 | −$0.83 | −$50.00 | +97.6% | 3 |
| Current fiscal year (2026) | −$3.65 | −$8.00 | −$0.96 | −$336.00 | +98.9% | 3 |
| Next fiscal year (2027) | −$4.68 | −$6.60 | −$3.49 | −$3.65 | −28.2% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IRLA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
IRLA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IRLA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$8.80 | −$1.40 | −$1.10 | −$1.20 | −$1.20 | −86.4% | 0 up · 0 down |
| Current fiscal year (2026) | −$5.30 | −$1.48 | −$3.65 | −$3.65 | −$3.65 | −31.1% | 0 up · 0 down |
| Next fiscal year (2027) | −$26.10 | −$5.76 | −$4.68 | −$4.68 | −$4.68 | −82.1% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IRLA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IRLA beat in 2 of 4.
What analysts expect from IRLA
9 analysts cover IRulya Therapeutics; their consensus rating is strong buy (4.56 on a 1–5 scale, where 5 is a strong buy). The average price target is $75.00, 134.2% above the latest close of $32.03. Analysts expect earnings of −$3.65 per share for 2026, +98.9% from a year earlier. For 2027 the average estimate is −$4.68 per share. IRulya Therapeutics beat the EPS estimate in 2 of the last 4 quarters.
Related: IRLA income statement, IRLA key metrics, IRLA chart. See the IRLA stock overview for the latest quote and news.
IRLA forecast FAQ
What is IRulya Therapeutics's price target?
The average analyst price target for IRulya Therapeutics is $75.00, 134.2% above the latest close of $32.03.
Is IRulya Therapeutics a buy, hold or sell?
Of 9 analysts covering IRulya Therapeutics, 6 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is IRulya Therapeutics's EPS forecast?
Analysts forecast −$3.65 per share for 2026 (range −$8.00 to −$0.96); for 2027 the estimate is −$4.68.
When does IRulya Therapeutics report earnings?
IRulya Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.83.
Does IRulya Therapeutics usually beat earnings estimates?
IRulya Therapeutics reported EPS at or above the analyst estimate in 2 of the last 4 quarters.